Please login to the form below
cetuximab
This page shows the latest cetuximab news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
The study assessed the candidate monalizumab in combination with cetuximab compared to cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who
Latest news
-
Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer
Braftovi (encorafenib) combined with has been recommended Merck KGaA’s EGFR-targeting antibody Erbitux (cetuximab) has been recommended as a second-line treatment for BRAF-positive metastatic colorectal cancer (mCRC).
-
MSD’s Keytruda scores another EU okay, in head and neck cancer
cancer for a decade – the EXTREME regimen of Eli Lilly’s Erbitux (cetuximab) with a platinum drug plus 5-FU – in the PD-L1-expressing group.
-
Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial
It also sells gastrointestinal cancer antibodies Erbitux (cetuximab) and recently launched Cyramza (ramucirumab), but was a late entrant into the cancer immunotherapy sector, and the Armo deal is viewed as a
-
Innate Pharma and AstraZeneca take monalizumab into phase 3
The biotech – based in Marseille, France – will proceed into a phase 3 trial evaluating monalizumab in combination with Eli Lilly’s Erbitux (cetuximab) in patients suffering from recurrent or metastatic squamous
-
Pfizer adds Array to cancer arsenal with $11bn acquisition
However its greatest potential is in colorectal cancer. A triplet combination of Braftovi and Mektovi plus cetuximab in the Phase 3 BEACON trial in BRAF-mutant metastatic colorectal cancer (mCRC) showed
More from news
Approximately 5 fully matching, plus 74 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
Mirna hires former Pfizer director as CMO
Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- AstraZeneca’s mild combination asthma reliever approved in UK
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
